Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRI + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
FOLFIRI + bevacizumab is a combination chemotherapy and targeted therapy regimen used primarily for the treatment of metastatic colorectal cancer. The regimen consists of four drugs: - Bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and reducing tumor blood supply. - Fluorouracil (5-FU), an antimetabolite that incorporates into DNA and RNA to inhibit cell division. - Irinotecan, a topoisomerase I inhibitor that prevents DNA from uncoiling and duplicating. - Leucovorin (folinic acid), which enhances the effectiveness of fluorouracil. This combination works synergistically by attacking cancer cells through different mechanisms—chemotherapy agents disrupt DNA synthesis and cell division, while bevacizumab targets tumor vasculature. It is administered intravenously in cycles every two weeks. The primary indication is metastatic colorectal cancer; it may also be used for other gastrointestinal cancers such as appendiceal adenocarcinoma and small bowel adenocarcinoma[1][2][4][5][8].
- Brand names
- Avastin (for bevacizumab)Camptosar (for irinotecan)
- Other names
- folfiri-bevacizumab regimenbevacizumab-folfiri
02
Targets
Beyond the preview
Go deeper on FOLFIRI + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRI + bevacizumab.